Enovis (ENOV) Net Income towards Common Stockholders (2010 - 2026)
Enovis' (ENOV) quarterly Net Income towards Common Stockholders came in at -$1.0 million in Q3 2026, up 97.17% year-over-year from -$525447.2 in Q3 2025, and up 87.74% quarter-over-quarter from -$8.4 million in Q2 2026.
Analysis
Enovis (ENOV) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Enovis (ENOV) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$1.0 million the latest figure, recorded in Q3 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 97.17% year-over-year to -$1.0 million in Q3 2026; TTM through Jul 2026 was -$1.1 billion, a 33.16% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 43.5% from the prior year.
- Net Income towards Common Stockholders was -$1.0 million for Q3 2026 at Enovis, up from -$8.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $77.0 million in Q3 2022 and troughed at -$703.2 million in Q4 2024.
- A 5-year average of -$114.6 million and a median of -$27.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders jumped 168.78% in 2022 and plunged 22931.17% in 2024, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at -$38.6 million in 2022, then surged by 107.98% to $3.1 million in 2023, then sank by 22931.17% to -$703.2 million in 2024, then rose by 25.99% to -$520.5 million in 2025, then jumped by 99.8% to -$1.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$1.0 million (Q3 2026), -$8.4 million (Q2 2026), and -$520.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.70 Bn | 177.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 126.82 Bn | 121.60 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.93 Bn | 109.11 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.83 Bn | 101.36 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 64.79 Bn | 64.25 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.83 Bn | 45.58 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 32.99 Bn | 31.53 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.14 Bn | 30.20 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.75 Bn | 20.27 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Enovis | 1.07 Bn | 1.06 Bn | 359.25 Mn | -1.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | -1.04 Mn |
| Apr 3, 2026 | -8.45 Mn |
| Dec 31, 2025 | -520.45 Mn |
| Oct 3, 2025 | -570.91 Mn |
| Jul 4, 2025 | -36.55 Mn |
| Apr 4, 2025 | -55.71 Mn |
| Dec 31, 2024 | -703.20 Mn |
| Sep 27, 2024 | -31.26 Mn |
| Jun 28, 2024 | -18.51 Mn |
| Mar 29, 2024 | -71.84 Mn |
| Dec 31, 2023 | 3.08 Mn |
| Sep 29, 2023 | -2.84 Mn |
| Jun 30, 2023 | -9.81 Mn |
| Mar 31, 2023 | -23.16 Mn |
| Dec 31, 2022 | -38.57 Mn |
| Sep 30, 2022 | -66.48 Mn |
| Jul 1, 2022 | 76.99 Mn |
| Apr 1, 2022 | 15.07 Mn |
| Dec 31, 2021 | -570,000.00 |
| Oct 1, 2021 | 25.85 Mn |